Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection (GS-US-320-1092)

IRB
CHLA-18-00070
A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection (GS-US-320-1092)

To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitis B.

Study Details
Clinical Trials Government Identifier
NCT02932150
Keywords
tenofovir alafenamide TAF, hepatitis B, teens, adolescents
Eligibility
Children age 2 to < 18 years old with documented evidence of Chronic Hepatitis B (e.g., HBsAg-positive for ≥ 6 months)
Does this study also recruit healthy volunteers?
No
Enrollment Status
Open
Coordinator Contact
Sharon Tang
Contact Email
shatang@chla.usc.edu